Recent Developments in Glioblastoma-On-A-Chip for Advanced Drug Screening Applications.

Autor: Maity S; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.; Department of Orthopedic Surgery, Duke University School of Medicine, Duke University, Durham, NC, 27705, USA., Bhuyan T; Department of Applied Biology, School of Biological Sciences, University of Science & Technology Meghalaya, Meghalaya, 793101, India., Jewell C; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Kawakita S; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Sharma S; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Nguyen HT; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Hassani Najafabadi A; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Ermis M; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.; Center of Excellence in Biomaterials and Tissue Engineering, Middle East Technical University, Ankara, 06800, Turkey., Falcone N; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Chen J; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Mandal K; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Khorsandi D; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Yilgor C; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Choroomi A; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Torres E; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Mecwan M; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., John JV; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Akbari M; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.; Laboratory for Innovations in Micro Engineering (LiME), Department of Mechanical Engineering, University of Victoria, Victoria, BC, V8P 5C2, Canada.; Biotechnology Center, Silesian University of Technology, Akademicka 2A, Gliwice, 44-100, Poland., Wang Z; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Moniz-Garcia D; Department of Neurosurgery, Mayo Clinic Florida, Jacksonville, FL, 32224, USA., Quiñones-Hinojosa A; Department of Neurosurgery, Mayo Clinic Florida, Jacksonville, FL, 32224, USA., Jucaud V; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Dokmeci MR; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA., Khademhosseini A; Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
Jazyk: angličtina
Zdroj: Small (Weinheim an der Bergstrasse, Germany) [Small] 2024 Nov 13, pp. e2405511. Date of Electronic Publication: 2024 Nov 13.
DOI: 10.1002/smll.202405511
Abstrakt: Glioblastoma (GBM) is an aggressive form of cancer, comprising ≈80% of malignant brain tumors. However, there are no effective treatments for GBM due to its heterogeneity and the presence of the blood-brain barrier (BBB), which restricts the delivery of therapeutics to the brain. Despite in vitro models contributing to the understanding of GBM, conventional 2D models oversimplify the complex tumor microenvironment. Organ-on-a-chip (OoC) models have emerged as promising platforms that recapitulate human tissue physiology, enabling disease modeling, drug screening, and personalized medicine. There is a sudden increase in GBM-on-a-chip models that can significantly advance the knowledge of GBM etiology and revolutionize drug development by reducing animal testing and enhancing translation to the clinic. In this review, an overview of GBM-on-a-chip models and their applications is reported for drug screening and discussed current challenges and potential future directions for GBM-on-a-chip models.
(© 2024 Wiley‐VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: